Wednesday August 23rd 2017

Receptos enrols first patients in Phase III study of multiple sclerosis drug

US-based biopharmaceutical firm Receptos has enrolled the first patients in the Phase III portion of RADIANCE, its Phase II/III trial of RPC1063 in relapsing multiple sclerosis (RMS). (Source: Drug Development Technology)

MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Sales here.

Read More – 

Receptos enrols first patients in Phase III study of multiple sclerosis drug

Leave a Comment

More from category

Novartis launches MS study using data collected from smartphones
Novartis launches MS study using data collected from smartphones

Novartis (NYSE:NVS) said today that it is launching a research study to better understand the daily challenges facing [Read More]

McDonald criteria: MS diagnosis guidelines
McDonald criteria: MS diagnosis guidelines

Learn about the McDonald criteria. What is dissemination in space, what is dissemination in time, and what additional [Read More]

Multiple sclerosis: Are we close to a cure?
Multiple sclerosis: Are we close to a cure?

Read this article: Multiple sclerosis: Are we close to a cure? [Read More]

Medical News Today: McDonald criteria: MS diagnosis guidelines
Medical News Today: McDonald criteria: MS diagnosis guidelines

Learn about the McDonald criteria. What is dissemination in space, what is dissemination in time, and what additional [Read More]

Medical News Today: Multiple sclerosis: Are we close to a cure?
Medical News Today: Multiple sclerosis: Are we close to a cure?

Discoveries and breakthroughs in multiple sclerosis research are building momentum, but just how close are we to [Read More]